These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 14813807)

  • 1. Toxic factor(s) in vaccinia virus and its neutralization by penicillin; a preliminary communication.
    MURTHY VN
    Ind Med Gaz; 1950 Nov; 85(11):487-8. PubMed ID: 14813807
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vaccine virus and penicillin].
    FASQUELLE R
    C R Seances Soc Biol Fil; 1947 Jan; 141(1-2):37. PubMed ID: 20268199
    [No Abstract]   [Full Text] [Related]  

  • 3. [Production of penicillinase in cultures of bacterial flora of the vagina in syphilitics in the course of penicillin therapy].
    BORELLI G
    Arch Ital Dermatol Sifilogr Venereol; 1951; 24(2):103-8. PubMed ID: 14857990
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting of vaccinia virus using biotin-avidin viral coating and biotinylated antibodies.
    Purow B; Staveley-O'Carroll K
    J Surg Res; 2005 Jan; 123(1):49-54. PubMed ID: 15652950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on vaccinia virus. II. Neutralization of vaccinia virus by normal guinea pig serum.
    BRIODY BA; LEDINKO N; STANNARD C
    J Immunol; 1951 Nov; 67(5):413-22. PubMed ID: 14898077
    [No Abstract]   [Full Text] [Related]  

  • 6. THE CHEMICAL COMPOSITION OF VACCINIA VIRUS.
    ZWARTOUW HT
    J Gen Microbiol; 1964 Jan; 34():115-23. PubMed ID: 14121210
    [No Abstract]   [Full Text] [Related]  

  • 7. The toxic activity of vaccinia virus in tissue culture.
    BROWN A; MAYYASI SA; OFFICER JE
    J Infect Dis; 1959; 104(2):193-202. PubMed ID: 13654808
    [No Abstract]   [Full Text] [Related]  

  • 8. The A17L gene product of vaccinia virus is exposed on the surface of IMV.
    Wallengren K; Risco C; Krijnse-Locker J; Esteban M; Rodriguez D
    Virology; 2001 Nov; 290(1):143-52. PubMed ID: 11882999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel vaccinia-neutralization assay based on reporter-gene expression.
    Manischewitz J; King LR; Bleckwenn NA; Shiloach J; Taffs R; Merchlinsky M; Eller N; Mikolajczyk MG; Clanton DJ; Monath T; Weltzin RA; Scott DE; Golding H
    J Infect Dis; 2003 Aug; 188(3):440-8. PubMed ID: 12870127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ECZEMA VACCINATUM: A CASE REMINDER.
    KITZMAN R
    Marquette Med Rev; 1964 May; 30():110-2. PubMed ID: 14158086
    [No Abstract]   [Full Text] [Related]  

  • 11. Zoonotic vaccinia virus infection in Brazil: clinical description and implications for health professionals.
    de Souza Trindade G; Drumond BP; Guedes MI; Leite JA; Mota BE; Campos MA; da Fonseca FG; Nogueira ML; Lobato ZI; Bonjardim CA; Ferreira PC; Kroon EG
    J Clin Microbiol; 2007 Apr; 45(4):1370-2. PubMed ID: 17287326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The viruses of variola, vaccina, cowpox and ectromelia. Neutralization tests on the chorio-allantois with unabsorbed and absorbed immune sera.
    DOWNIE AW; McCARTHY K
    Br J Exp Pathol; 1950 Dec; 31(6):789-96. PubMed ID: 14801363
    [No Abstract]   [Full Text] [Related]  

  • 13. Extracellular enveloped vaccinia virus escapes neutralization.
    Ichihashi Y
    Virology; 1996 Mar; 217(2):478-85. PubMed ID: 8610439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies.
    Borges MB; Kato SE; Damaso CR; Moussatché N; da Silva Freire M; Lambert Passos SR; do Nascimento JP
    Biologicals; 2008 Mar; 36(2):105-10. PubMed ID: 17892944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity, pathogenicity, and transmissibility of a recombinant vaccinia virus in calves.
    Wedman EE; Smith AW; Oliver RE
    Am J Vet Res; 1988 Dec; 49(12):2018-21. PubMed ID: 3239835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct.
    Mempel M; Isa G; Klugbauer N; Meyer H; Wildi G; Ring J; Hofmann F; Hofmann H
    J Invest Dermatol; 2003 Mar; 120(3):356-8. PubMed ID: 12603846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the influence of the spreading factor to the potency of the vaccinia virus.
    SUTO H; ISHIKAWA T
    Kitasato Arch Exp Med; 1952 Oct; 25(2):109-14. PubMed ID: 13097704
    [No Abstract]   [Full Text] [Related]  

  • 18. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An unusual infection with the vaccinia virus (poxvirus officinale)].
    Kirsch WD; Handrick W; Keller HP
    Dtsch Med Wochenschr; 1973 Jun; 98(26):1292-4. PubMed ID: 4714029
    [No Abstract]   [Full Text] [Related]  

  • 20. Passatempo virus, a vaccinia virus strain, Brazil.
    Leite JA; Drumond BP; Trindade GS; Lobato ZI; da Fonseca FG; dos SJ; Madureira MC; Guedes MI; Ferreira JM; Bonjardim CA; Ferreira PC; Kroon EG
    Emerg Infect Dis; 2005 Dec; 11(12):1935-8. PubMed ID: 16485483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.